All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Corporate Bonds

M&A funding spikes as AstraZeneca lands $7bn sub-curve

Molecule from AstraZeneca media gallery May21 575x375

AstraZeneca, the UK drug company, showed the eager demand for merger and acquisition financings this week when it achieved ultra-tight pricing on a $7bn bond issue to fund its acquisition of US biotech firm Alexion Pharmaceuticals.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree